The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1571
ISSUE 1571
May 6, 2019
Insulins for Type 2 Diabetes
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
May 6, 2019 (Issue: 1571)
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is <7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Insulins for Type 2 Diabetes
Article code: 1571a
Electronic, downloadable article - $45
Article code: 1571a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
